A Study Comparing Sacituzumab Tirumotecan to Other Treatments for Recurrent Cervical Cancer
Phase 3
686
about 3.9 years
18+
Female only
38 sites in AK, AL, AZ +17
What this study is about
This trial is testing sacituzumab tirumotecan, a new treatment, against other treatments (Treatment of Physician's Choice or TPC) as a second-line treatment for people with recurrent or metastatic cervical cancer. The goal is to see if sacituzumab tirumotecan helps patients live longer and has fewer side effects compared to the other treatments.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Sacituzumab Tirumotecan
- 2.Receive Tisotumab Vedotin
- 3.Take Gemcitabine
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
gemcitabine, irinotecan, pemetrexed, tisotumab vedotin, topotecan, vinorelbine
injection (Injection), oral (Oral Capsule)
Primary: Number of Participants Discontinuing Study Treatment Due to an AE in Sacituzumab Tirumotecan Run-in, Number of Participants Experiencing One or More Adverse Events (AEs) in Sacituzumab Tirumotecan Run-in, Objective Response Rate (ORR) in Sacituzumab Tirumotecan Run-in, Overall Survival (OS) in Phase 3 Portion
Secondary: Change from Baseline in EORTC QLQ-C30 Global Health Status (Item 29) and Quality of Life (Item 30) Combined Score in Phase 3 Portion, Change from Baseline in EORTC QLQ-C30 Physical Functioning Score in Phase 3 Portion, Change from Baseline in EORTC QLQ-C30 Role Functioning Score in Phase 3 Portion, Duration of Response (DOR) in Phase 3 Portion, Number of Participants Discontinuing Study Treatment Due to an AE in Phase 3 Portion, Number of Participants Experiencing One or More AEs in Phase 3 Portion, ORR in Phase 3 Portion, Progression-free Survival (PFS) in Phase 3 Portion
Oncology